England

England

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.69 (0.60 - 0.78) 2019 Modelled IHME
0.69 (0.60 - 0.78) 2018 Modelled IHME
0.69 (0.60 - 0.78) 2017 Modelled IHME
0.69 (0.61 - 0.78) 2016 Modelled IHME
0.69 (0.61 - 0.78) 2015 Modelled IHME
0.7 (0.61 - 0.78) 2014 Modelled IHME
0.7 (0.61 - 0.78) 2013 Modelled IHME
0.7 (0.61 - 0.79) 2012 Modelled IHME
0.7 (0.61 - 0.79) 2011 Modelled IHME
0.7 (0.61 - 0.79) 2010 Modelled IHME
0.7 (0.61 - 0.79) 2009 Modelled IHME
0.7 (0.61 - 0.79) 2008 Modelled IHME
0.7 (0.61 - 0.79) 2007 Modelled IHME
0.7 (0.61 - 0.79) 2006 Modelled IHME
0.7 (0.61 - 0.79) 2005 Modelled IHME
0.7 (0.61 - 0.79) 2004 Modelled IHME
0.69 (0.60 - 0.78) 2003 Modelled IHME
0.68 (0.59 - 0.78) 2002 Modelled IHME
0.68 (0.59 - 0.77) 2001 Modelled IHME
0.67 (0.59 - 0.76) 2000 Modelled IHME
0.67 (0.59 - 0.76) 1999 Modelled IHME
0.67 (0.58 - 0.77) 1998 Modelled IHME
0.68 (0.58 - 0.77) 1997 Modelled IHME
0.68 (0.58 - 0.77) 1996 Modelled IHME
0.68 (0.58 - 0.77) 1995 Modelled IHME
0.68 (0.58 - 0.77) 1994 Modelled IHME
0.68 (0.58 - 0.77) 1993 Modelled IHME
0.67 (0.58 - 0.77) 1992 Modelled IHME
0.67 (0.58 - 0.77) 1991 Modelled IHME
0.67 (0.58 - 0.77) 1990 Modelled IHME
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.07 (0.05 - 0.09) 2019 Modelled IHME
0.07 (0.05 - 0.09) 2018 Modelled IHME
0.08 (0.06 - 0.10) 2017 Modelled IHME
0.2 (0.15 - 0.25) 2016 Modelled IHME
0.31 (0.23 - 0.40) 2015 Modelled IHME
0.32 (0.24 - 0.40) 2014 Modelled IHME
0.32 (0.24 - 0.40) 2013 Modelled IHME
0.32 (0.24 - 0.41) 2012 Modelled IHME
0.32 (0.24 - 0.41) 2011 Modelled IHME
0.32 (0.24 - 0.41) 2010 Modelled IHME
0.32 (0.24 - 0.41) 2009 Modelled IHME
0.32 (0.24 - 0.41) 2008 Modelled IHME
0.32 (0.24 - 0.41) 2007 Modelled IHME
0.32 (0.24 - 0.41) 2006 Modelled IHME
0.32 (0.24 - 0.41) 2005 Modelled IHME
0.32 (0.24 - 0.41) 2004 Modelled IHME
0.32 (0.24 - 0.41) 2003 Modelled IHME
0.32 (0.24 - 0.41) 2002 Modelled IHME
0.32 (0.24 - 0.41) 2001 Modelled IHME
0.32 (0.24 - 0.41) 2000 Modelled IHME
0.32 (0.24 - 0.41) 1999 Modelled IHME
0.33 (0.24 - 0.41) 1998 Modelled IHME
0.33 (0.25 - 0.42) 1997 Modelled IHME
0.33 (0.25 - 0.42) 1996 Modelled IHME
0.33 (0.25 - 0.42) 1995 Modelled IHME
0.33 (0.25 - 0.42) 1994 Modelled IHME
0.33 (0.25 - 0.42) 1993 Modelled IHME
0.33 (0.25 - 0.42) 1992 Modelled IHME
0.33 (0.25 - 0.42) 1991 Modelled IHME
0.34 (0.25 - 0.42) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (10 - 14) 2019 Modelled IHME
12 (10 - 14) 2018 Modelled IHME
12 (10 - 14) 2017 Modelled IHME
12 (10 - 14) 2016 Modelled IHME
12 (10 - 14) 2015 Modelled IHME
12 (10 - 14) 2014 Modelled IHME
12 (10 - 14) 2013 Modelled IHME
12 (10 - 14) 2012 Modelled IHME
12 (10 - 14) 2011 Modelled IHME
12 (10 - 14) 2010 Modelled IHME
12 (10 - 14) 2009 Modelled IHME
12 (10 - 14) 2008 Modelled IHME
12 (10 - 14) 2007 Modelled IHME
12 (10 - 14) 2006 Modelled IHME
12 (10 - 14) 2005 Modelled IHME
12 (10 - 14) 2004 Modelled IHME
12 (10 - 14) 2003 Modelled IHME
12 (10 - 14) 2002 Modelled IHME
12 (10 - 14) 2001 Modelled IHME
12 (10 - 15) 2000 Modelled IHME
12 (10 - 15) 1999 Modelled IHME
12 (10 - 15) 1998 Modelled IHME
12 (10 - 15) 1997 Modelled IHME
12 (10 - 15) 1996 Modelled IHME
13 (10 - 15) 1995 Modelled IHME
13 (10 - 15) 1994 Modelled IHME
13 (10 - 15) 1993 Modelled IHME
13 (10 - 15) 1992 Modelled IHME
13 (11 - 15) 1991 Modelled IHME
13 (11 - 15) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
None
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Yes
Eligible for HCV generic medicines

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.1 (0.89 - 1.34) 2019 Modelled IHME
1.1 (0.89 - 1.34) 2018 Modelled IHME
1.1 (0.89 - 1.34) 2017 Modelled IHME
1.33 (1.08 - 1.63) 2016 Modelled IHME
1.61 (1.31 - 1.98) 2015 Modelled IHME
1.71 (1.39 - 2.10) 2014 Modelled IHME
1.8 (1.47 - 2.21) 2013 Modelled IHME
1.86 (1.52 - 2.29) 2012 Modelled IHME
1.91 (1.55 - 2.34) 2011 Modelled IHME
1.92 (1.56 - 2.36) 2010 Modelled IHME
1.92 (1.56 - 2.36) 2009 Modelled IHME
1.91 (1.56 - 2.35) 2008 Modelled IHME
1.91 (1.55 - 2.35) 2007 Modelled IHME
1.89 (1.54 - 2.33) 2006 Modelled IHME
1.88 (1.53 - 2.32) 2005 Modelled IHME
1.78 (1.45 - 2.19) 2004 Modelled IHME
1.56 (1.27 - 1.92) 2003 Modelled IHME
1.3 (1.06 - 1.60) 2002 Modelled IHME
1.08 (0.88 - 1.33) 2001 Modelled IHME
0.98 (0.79 - 1.20) 2000 Modelled IHME
0.97 (0.78 - 1.18) 1999 Modelled IHME
0.96 (0.77 - 1.17) 1998 Modelled IHME
0.95 (0.77 - 1.16) 1997 Modelled IHME
0.94 (0.76 - 1.15) 1996 Modelled IHME
0.94 (0.76 - 1.15) 1995 Modelled IHME
0.94 (0.76 - 1.15) 1994 Modelled IHME
0.94 (0.76 - 1.15) 1993 Modelled IHME
0.94 (0.76 - 1.15) 1992 Modelled IHME
0.93 (0.76 - 1.15) 1991 Modelled IHME
0.93 (0.76 - 1.15) 1990 Modelled IHME
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
28 2018 Survey/reported Public Health England, 2020

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
30.7 (26.90 - 34.60) 2013 Modelled Degenhardt L et al, 2017
55 2018 Survey/reported Public Health England, 2020
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
41 (37 - 45) 2019 Modelled IHME
41 (38 - 45) 2018 Modelled IHME
41 (38 - 45) 2017 Modelled IHME
41 (37 - 45) 2016 Modelled IHME
41 (37 - 45) 2015 Modelled IHME
41 (37 - 45) 2014 Modelled IHME
41 (37 - 45) 2013 Modelled IHME
41 (37 - 45) 2012 Modelled IHME
41 (37 - 45) 2011 Modelled IHME
40 (37 - 44) 2010 Modelled IHME
40 (36 - 44) 2009 Modelled IHME
40 (36 - 44) 2008 Modelled IHME
40 (36 - 44) 2007 Modelled IHME
40 (36 - 44) 2006 Modelled IHME
39 (36 - 44) 2005 Modelled IHME
39 (36 - 43) 2004 Modelled IHME
39 (36 - 43) 2003 Modelled IHME
39 (36 - 43) 2002 Modelled IHME
40 (36 - 43) 2001 Modelled IHME
39 (36 - 43) 2000 Modelled IHME
40 (36 - 44) 1999 Modelled IHME
40 (36 - 44) 1998 Modelled IHME
40 (36 - 44) 1997 Modelled IHME
40 (36 - 44) 1996 Modelled IHME
40 (36 - 44) 1995 Modelled IHME
40 (36 - 44) 1994 Modelled IHME
40 (36 - 44) 1993 Modelled IHME
40 (36 - 44) 1992 Modelled IHME
40 (36 - 44) 1991 Modelled IHME
40 (36 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
None
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Yes
Eligible for HCV generic medicines

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
0.69 (%)
2019
(0.6 - 0.78(%))
IHME
HCV (RNA/cAg+)
1.1 (%)
2019
(0.89 - 1.34(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,069
2019
(937 - 1,196)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,158
2019
(1,909 - 2,385)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.07 (%)
2019, latest modelled
(0.05 - 0.09(%))
IHME

Prevalence PWID

HCV
55 (%)
2018, survey/surveillance
Public Health England, 2020

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines